Slowing the Rise in Healthcare

"A Health Care Success Story" describes a success in reducing costs by increasing preventative and relying less on payment for drugs and services later on as an  illness becomes lethal.

America's Health-care System Remains Dysfunctional, But it Could be Made Better

The Economist editorial "How to Fix Obamacare" has many good points, but principally it is not a good that to free markets well, especially as practiced in the U.S. with third party payers and zero transparency.

Surprise $117,000 Medical Bill

After Surgery, Surprise $117,000 Medical Bill from Doctor He Didn't Know

CVS's front door to the health establishment foray

A while back I thought highly of CVS's front door to the health establishment foray, but a survey of drug pricing put them at the $500 price level for a drug that CostCo offers for $15.  Oops  

Trans Fats

For years people chose margarine over butter for health reasons.  It's like the Woody Allen movie where he awakes in the future and is told that chocolate and steaks is so much better than health food.  The truth is that it is.

Mad Money's Jim Cramer

It's a shame the administration did not use the smart team they put together for the election to roll out the health care program.  According to Cramer, the Obama-care webpage is a CRM (Customer Relations Manager) that could have used Salesforce.com as the off the shelf application,  Google searching and verifying among the various data sets and Amazon running the system with it's IT utility services.
Barack Obama ought to can Sibelius as Secretary of Health and Human Services and put Jim in charge instead.

Obamacare, Retooled

Professor Tyler Cowen's proposals in today's New York Times lack some free market trust busting ideas that an Economist at George Mason University might want to consider.  How about lowering entry barriers for health providers so that a walk in walk out surgical procedure in a clinic is more reasonable than $50,000 at a clip? How about demanding out of patent drugs be used in all instances where public subsidy of cost is required.  Otherwise and extraordinary drug's expense is for the patient and his non subsidized insurer to shoulder.  I am sure there are other ideas to control costs, so let the market develop them easily.